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Abstract
Purpose: Pre-exposure prophylaxis (PrEP) is an effective strategy to prevent HIV. However, low uptake of daily
oral PrEP since Food and Drug Administration approval and low medication adherence among users have stim-
ulated the investigation of other modalities for delivery, such as injectable PrEP and on-demand PrEP. The ob-
jective of this study was to determine the demographic and behavioral predictors of willingness to try alternative
PrEP delivery mechanisms among young men who have sex with men (YMSM) who stated that they were un-
willing to try daily oral PrEP.
Methods: YMSM in California were recruited through geosocial networking applications; we analyzed a sub-
sample who stated that they were either ambivalent about trying or unwilling to try daily oral PrEP (n = 265).
We used chi-square and Fisher’s exact tests to determine characteristics associated with willingness to try inject-
able PrEP, willingness to try on-demand PrEP, and willingness to try either alternative form.
Results: For individuals who stated that they would not be willing to try daily oral PrEP,*85% were willing to
try on-demand and/or injectable PrEP. Individuals who reported some college or more reported greater willing-
ness to try injectable PrEP (adjusted odds ratio [aOR]: 2.92; 95% confidence interval [CI]: 1.32–6.46), on-
demand PrEP (aOR: 2.28; 95% CI: 1.06–4.90), or either method (aOR: 5.54; 95% CI: 1.78–17.22).
Conclusion: Future research should determine how to enhance uptake of emerging forms of PrEP among the
individuals most at risk for HIV.
Keywords: gay/bisexual men, HIV pre-exposure prophylaxis, HIV prevention, men who have sex with men
Introduction
Pre-exposure prophylaxis (PrEP) is a biomedical HIVprevention strategy that can greatly reduce the chances
of acquiring HIV among HIV-negative individuals.1 In
2012, the U.S. Food and Drug Administration approved
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for
daily oral PrEP.2 Models indicate that daily oral PrEP can re-
duce an individual’s likelihood of contracting HIV by be-
tween 96% and 99% for rectal exposures.3 PrEP represents
a promising strategy for reducing HIV burden among the
most heavily affected communities, including gay, bisexual,
and other men who have sex with men (MSM), but low up-
take of daily oral PrEP and suboptimal adherence to daily
oral PrEP indicate that other modalities may be warranted.
In the largest PrEP trials and demonstration projects to
date, between 32% and 86% of participants had detectable
tenofovir (TFV) or TFV-diphosphate levels in plasma or pe-
ripheral blood mononuclear cells, and much lower propor-
tions had biomarker evidence of daily adherence.1,4–7 In
addition, uptake of daily oral PrEP has been low. In the
One Thousand Strong Cohort study of MSM in the United
States, Parsons et al. found that 4% of participants had
been prescribed PrEP and proposed a motivational cascade
for improving uptake and adherence.8 A study by Hoots
et al. found similar uptake among men participating in the
1Department of Health and Mental Health Services, Los Angeles LGBT Center, Los Angeles, California.
2Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los
Angeles, California.
3Department of Social Welfare, Luskin School of Public Affairs, University of California, Los Angeles, Los Angeles, California.
4Center for Clinical AIDS Research and Education (CARE), University of California, Los Angeles, Los Angeles, California.
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National HIV Behavioral Surveillance (NHBS) survey with
only 4% of men reporting PrEP use.9 In contrast, 57% of
NHBS participants have an indication for PrEP based on
Centers for Disease Control and Prevention (CDC) Guide-
lines.9 To increase uptake and acceptability, more episodic
regimens, such as injectable and on-demand PrEP, have re-
cently been investigated.10,11
Cabotegravir is an investigational integrase inhibitor that
has been shown in animal models to provide robust protec-
tion against simian/human immunodeficiency virus (SHIV)
challenge through rectal, vaginal, and intravenous routes.12
The first Phase IIa study that investigated cabotegravir as
long-acting injectable (LAI) PrEP in HIV-negative men
found that two simultaneous gluteal injections of long-
acting cabotegravir (2 mL each, 800 mg total) every 12
weeks was a suboptimal regimen.13 In response to these
findings, a second Phase IIa trial (HPTN 077 in Brazil,
sub-Saharan Africa, and the United States) was modified
to evaluate an alternative dose of 600 mg (given as a single
3 mL injection) every 8 weeks after an initial 4-week injec-
tion interval.14 Results from the primary analysis showed
that LAI cabotegravir was tolerated well by low-risk
HIV-negative men and women and the findings supported
development of LAI cabotegravir for HIV prevention in
men and women using the 600 mg dose (given as a single
3 mL injection) administered every 8 weeks after an initial
4-week injection interval.14
Data from the ECLAIR study found that participant sat-
isfaction with cabotegravir was high, with most individuals
indicating a desire to continue receiving PrEP through in-
jections instead of taking an oral version of cabotegravir.15
In the P18 cohort study among young MSM in New York,
81% of respondents stated that they were willing to use in-
jectable PrEP and 79% of respondents stated that they
would prefer injectable PrEP at 3-month intervals when
compared with a daily oral pill.16 In another study among
1071 MSM in the United States, Parsons et al. found that
LAI PrEP administered every 3 months was acceptable
among 54% of respondents and preferred when compared
with daily oral formulations.17 In contrast, 35% preferred
daily oral pills, 34% preferred nonvisible implants, 25%
preferred injections, and 4% preferred visible implants
among another sample of MSM in the United States.10
On-demand PrEP involves an individual taking two doses of
FTC/TDF between 2 and 24 hours before sexual activity and
then subsequently taking one dose each at 24 and 48 hours
after the initial two doses.18 In the IPERGAY study, Molina
et al. showed that MSM who took active FTC/TDF on-demand
had a significantly lower incidence of HIV compared with in-
dividuals who took placebo in an on-demand schedule.18 The
authors reported that the active FTC/TDF group had a relative
reduction in HIV incidence of 86%. However, the median
number of doses used each month was 15. Given the high me-
dian number of doses each month, it is still unclear if truly ep-
isodic PrEP is sufficient to prevent HIV infection given
exposure.19,20 In addition, Parsons et al. have shown that indi-
viduals may be particularly inaccurate in predicting their future
sexual behavior.21
Although previous studies have compared the likelihood
of using different modalities of PrEP administration,22 no
studies to date have looked exclusively at respondents
who stated that they were unwilling to try daily oral
PrEP. The objective of this analysis was to determine the
demographic and behavioral predictors of willingness to
try alternative PrEP delivery mechanisms among the subset
of respondents in a large online sample of young MSM
(YMSM) in California who stated that they were unwilling
to try daily oral PrEP.
Methods
Participants and procedures
From July 9, 2015 to August 20, 2015, participants were
recruited in California through geosocial networking appli-
cations (apps) to complete a survey about PrEP. Geosocial
networking apps displayed push notifications and prospec-
tive participants were directed to a screener to assess eligibil-
ity. To meet screening criteria, prospective participants
needed to be (1) 18 to 29 years of age, (2) assigned a male
sex at birth and identify their gender as male, (3) sexually ac-
tive with other men in the past 5 years, (4) HIV negative, and
(5) a resident of California. Although participation was based
on sexual behavior with men as opposed to sexual orientation
identity, we also asked, ‘‘Do you consider yourself to be.’’
with options of (1) Heterosexual or straight, (2) Gay, (3) Les-
bian, (4) Bisexual, (5) Decline to Answer, or (6) Something
else, with an option to specify.
Individuals who met the screening criteria were directed to
the survey, which took *20 minutes to complete. The last
question collected the email address of the participant so
that they could receive a $25 gift card for participation.
The original sample was comprised of HIV-negative
YMSM in California, 18–29 years of age. The present anal-
ysis was conducted with a subset of individuals from the orig-
inal study with complete responses who identified as male,
had never used PrEP, and indicated that they were either
ambivalent about trying or unwilling to try daily oral PrEP.
Consent and institutional review board approval
Participants were recruited through push notifications on a
geosocial networking app. When they clicked on the notifica-
tion, they were redirected to a study website, which screened
for eligibility. An informed consent document was displayed
if participants passed the eligibility screener. After reading
the informed consent, participants could agree to participate
by clicking forward or decline study participation by exiting
the website. The study was approved by the North General
Institutional Review Board of the University of California,
Los Angeles.
Measures
Demographic measures included race/ethnicity (White,
Black/African American, Hispanic/Latino, or other/mixed),
age (dichotomized as 18–25 and 26–29), sexual orientation
identity (gay, bisexual, something else), sexual behavior
(with men only or men and women), employment (full
time, part time, full-time student, or other), education (di-
chotomized as less than college or some college and
above), income ($0–$9,999, $10,000–$29,000, or $30,000
or more), current insurance (yes or no), and citizenship status
(yes or no). Decline to answer options were provided for
all demographic questions. Race/ethnicity was a multiselect
question, whereas sexual orientation identity, sexual behavior,
342 BEYMER ET AL.
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employment, education, income, current insurance, and citi-
zenship status were single-select questions.
We asked about perceptions of the risk of getting HIV (low,
moderate, or high) and concern about becoming infected with
HIV (not concerned, somewhat concerned, or very con-
cerned). We also asked about timing of last HIV test (less
than 6 months ago, between 6 months and 1 year ago, and
more than 1 year ago/never), last sexually transmitted infec-
tion (STI) test (same categories), and if they had been diag-
nosed with an STI in the past year (yes or no). Lastly, we
asked about substance use in the last 6 months, number of
male sex partners in the last 6 months, whether the participant
used a condom all the time for anal sex, had receptive anal sex
with a man without a condom, insertive anal sex without a
condom with an HIV-positive man, or had any HIV-positive
male partners (all in the last 6 months). CDC risk score was
calculated using age group (18–28 vs. 29), number of male
sex partners in the last 6 months, number of times the individ-
ual had receptive anal sex with a man without a condom in the
last 6 months, number of HIV-positive male partners in the last
6 months, number of times the individual had insertive anal
sex with an HIV-positive man without a condom in the last
6 months, and use of methamphetamine in the last 6 months.
Willingness to use daily oral PrEP was measured on a 6-
item scale ranging from extremely likely to extremely un-
likely. Those who answered anything other than extremely
or very likely were considered either ‘‘ambivalent or unwill-
ing’’ to try daily oral PrEP. Therefore, individuals who stated
that they were somewhat likely, somewhat unlikely, very un-
likely, or extremely unlikely were classified in this ambiva-
lent or unwilling category. In addition, we used a sensitivity
analysis for participants who said that they were somewhat
unlikely, very unlikely, or extremely unlikely to try daily
oral PrEP to determine the validity of results.
Outcome measures
Participants were asked two additional yes/no questions
about different forms of PrEP, injectable and on-demand.
To assess willingness to try injectable PrEP, participants
were asked ‘‘Would you be more likely to take PrEP if it
was only a shot every 3 months instead of a daily pill?
(Assuming that both are equally effective).’’ To assess atti-
tudes about on-demand PrEP, participants were asked
‘‘Would you be more likely to take PrEP if you only had to
take the pill when you had sex instead of every day? (Assum-
ing that both are equally effective).’’ Participants who an-
swered yes to these questions were considered willing to try
the respective method(s). A third variable was created to indi-
cate those who were willing to try either alternative method
versus those who were not willing to try any form of PrEP.
Data analysis
Chi-square or Fisher’s exact tests were used to determine
the demographic and behavioral predictors of willingness to
try alternative PrEP delivery mechanisms (willing to try in-
jectable PrEP, willing to try on-demand PrEP, and willing
to try either alternative forms), adjusting for multiple com-
parisons with the Benjamini–Hochberg correction. Variables
that were significant at the bivariate level (alpha <0.05) were
included in separate multivariate logistic regression models
for each outcome.
Results
A total of 3842 individuals took the screener to assess sur-
vey eligibility. Of those who were screened, 1777 (46%) met
the inclusion criteria to complete the survey. The removal of
incomplete and duplicate surveys left a total of 761 unique
participants. Of the original sample of 761 participants,
687 (90.3%) had never taken PrEP, and 265 (38.6%) of
those who had complete responses were either ambivalent
about trying or unwilling to try daily oral PrEP (subsequently
referred to as ‘‘unwilling’’). In the sensitivity analysis, 105
participants were somewhat unlikely, very unlikely, or ex-
tremely unlikely to try daily oral PrEP.
When compared with those who were willing to try daily
oral PrEP, respondents who were unwilling to try daily oral
PrEP were more likely to be 18–25 years of age ( p = 0.002),
have an income of $30,000 or more ( p= 0.01), report receiv-
ing an HIV test within the last year ( p= 0.008), and report
not being at all concerned about becoming infected with
HIV ( p = 0.001).
The subset sample was racially/ethnically diverse: Black
(28.7%), Hispanic (27.5%), White (23.0%), and other/
mixed race (20.8%) (Table 1). Two-thirds of the sample
was 18–25 (66.8%) years of age and over three quarters
identified as gay (76.6%). Most of the sample indicated
they had sex with men only in the past 5 years (77.4%).
Forty-four percent of the sample was employed full time
and 75.5% completed some college or more. Many of the
participants (62.6%) indicated that they were at least some-
what concerned about becoming infected with HIV. Only
6.8% of the sample indicated that they felt their risk of get-
ting HIV was high, but 58% of individuals had a CDC risk
score that indicated that they were at high risk for HIV infec-
tion (Supplementary Table S1; Supplementary Data available
online at www.liebertpub.com/lgbt). The CDC risk score was
constructed based on an article by Smith et al. using data on
age group (18–28 vs. 29), number of male sex partners in the
last 6 months, number of times the individual had receptive
anal sex with a man without a condom in the last 6 months,
number of HIV-positive male partners in the last 6 months,
number of times the individual had insertive anal sex with
an HIV-positive man without a condom in the last 6 months,
and use of methamphetamine in the last 6 months.23 This is
also the risk algorithm that the CDC has used in its clinical
practice guidelines for PrEP.24 Individuals with scores
greater than or equal to 10 were classified as high risk based
on our risk score.
Nearly three-quarters (73.6%) of the sample indicated that
they would be more willing to try injectable PrEP than daily
oral PrEP. Race/ethnicity, employment status, education level,
insurance status, concern with getting HIV, time since last
HIV test, time since last STI test, any alcohol use in the last
6 months, and having had an HIV-positive male partner in
the last 6 months were significantly associated with willingness
to try injectable PrEP in bivariate analysis. After adjustment in a
multivariate model, only education level remained significant.
Those who had some college or more had higher odds of will-
ingness to try injectable PrEP (adjusted odds ratio [aOR]: 2.92;
95% confidence interval [CI]: 1.32–6.46) (Table 2).
Among the sample, 74.3% indicated that they would be
more willing to try on-demand dosing than daily oral PrEP.
With the exception of having had an HIV-positive male
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partner in the last 6 months, all variables significant in the
bivariate injectable PrEP analysis were significant in the bi-
variate on-demand analysis. After adjusting for other variables,
those with some college or more had 2.28 times higher odds
(95% CI: 1.06–4.90) of being willing to try on-demand PrEP,
but no other variables were significant in the model.
A large portion (85.3%) of the sample was willing to try in-
jectable and/or on-demand PrEP. In addition to the variables
that were significant in the bivariate on-demand analysis,
there were a few additional significant bivariate associations:
An individual’s own HIV risk rating, use of nitrates/poppers,
and having had receptive anal sex without a condom in the
last 6 months were also associated with willingness to try ei-
ther injectable or on-demand PrEP. Similarly, only education
level remained significant in a multivariate model. Those
who had at least some college had a higher odds (aOR: 5.54;
95% CI: 1.78–17.22) of willingness to try either injectable or
on-demand PrEP. Results were similar in the sensitivity analy-
ses (Supplementary Table S2).
Discussion
Among an internet sample of YMSM recruited in Califor-
nia, we found that 39% (n= 265) of PrEP-naive respondents
were either ambivalent about trying or unwilling to try daily
oral PrEP. Of the 265 individuals in this subset, 12% were
only unwilling to try injectable PrEP, 11% were only unwilling
to try on-demand PrEP, 15% were unwilling to try either form
of alternative PrEP, leaving 62% who were willing to try both
forms. YMSM who are unwilling to try any form of PrEP are
good candidates for nonbiomedical HIV prevention strategies.
Correct and consistent condom use may remain their best op-
tion for disease prevention. That said, more can be done to ed-
ucate these YMSM on the benefits of PrEP, especially as it
becomes more widely available in alternative formulations.
We did not detect associations between willingness to try
alternate forms of PrEP and concern for acquiring HIV or
having an HIV-positive partner in the last 6 months. Educa-
tional status was the only significant predictor of willingness
Table 2. Multivariate Logistic Regressions of Acceptability of Alternative Methods of Pre-Exposure
Prophylaxis by Demographic and Behavioral Characteristics Among Young Men
Who Have Sex with Men in California (n= 265)
Covariate
Injectable
OR (95% CI)
On demand
OR (95% CI)
Either injectable
or on demand
OR (95% CI)
Race/Ethnicity (ref =White)
Black/African American 1.12 (0.45–2.79) 0.40 (0.16–1.01) 0.39 (0.09–1.58)
Hispanic/Latino 1.80 (0.64–5.03) 1.22 (0.43–3.47) 1.29 (0.26–6.47)
Other/mixed 1.09 (0.41–2.92) 1.59 (0.52–4.89) 1.53 (0.27–8.59)
Employed (ref = employed full time)
Employed part time 0.56 (0.24–1.32) 0.56 (0.25–1.26) 0.40 (0.12–1.29)
Full-time student 0.89 (0.33–2.40) 1.38 (0.50–3.76) 2.19 (0.40–11.84)
Other 0.46 (0.18–1.21) 1.09 (0.40–3.00) 1.47 (0.33–6.52)
Education (ref = less than college)
Some college and above 2.92 (1.32–6.46)* 2.28 (1.06–4.90)* 5.54 (1.78–17.22)*
Current insurance (ref = yes)
No 0.65 (0.31–1.37) 0.81 (0.39–1.67) 0.63 (0.21–1.88)
How concerned are you about becoming infected with HIV (ref = not concerned)
Somewhat concerned 1.60 (0.70–3.68) 1.53 (0.65–3.61) 5.05 (1.14–22.47)
Very concerned 2.44 (1.08–5.51) 1.26 (0.58–2.76) 2.14 (0.65–7.09)
Last HIV test (ref = less than 6 months ago)
Between 6 months and 1 year ago 0.80 (0.21–3.05) 0.94 (0.25–3.58) 0.21 (0.03–1.47)
More than 1 year ago/never 1.21 (0.28–5.21) 3.91 (0.92–16.56) 0.23 (0.02–2.76)
Last STI test (ref = less than 6 months ago)
Between 6 months and 1 year ago 0.43 (0.12–1.58) 0.64 (0.17–2.43) 1.14 (0.17–7.54)
More than 1 year ago/never 1.18 (0.28–4.95) 0.44 (0.12–1.70) 12.41 (0.87–176.42)
Alcohol use in the last 6 months (ref = yes)
No 0.77 (0.33–1.81) 0.59 (0.27–1.28) 0.74 (0.22–2.50)
Had an HIV-positive male partner in the last 6 months (ref = no)
Yes 0.25 (0.09–0.69) — —
How would you rate your risk of getting HIV (ref = low)
Moderate — — 0.69 (0.24–2.00)
High — — 0.90 (0.09–9.05)
Popper use in the last 6 months (ref = no)
Yes — — 0.53 (0.13–2.20)
Had receptive anal sex with a man without a condom in the last 6 months (ref = no)
Yes — — 2.30 (0.74–7.13)
*p < 0.05.
CI, confidence interval; OR, odds ratio.
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to try alternate forms of PrEP in all three multivariate mod-
els. This finding could be explained by the hypothesis that
educated individuals have better access to, or better discern-
ment of, health resources and information.
Given low PrEP uptake9 as well as adherence barriers to the
once-daily oral PrEP formulation,25 individual, community,
and structural interventions are needed to increase awareness
of daily, injectable, and on-demand PrEP. For example, the
Los Angeles County Department of Public Health deployed
a social marketing campaign called GetPrEPLA.com, which
depicts PrEP users as superheroes in a comic book format.26
In New York City, the health department launched the ‘‘We
Stay Sure’’ campaign depicting same-sex couples as well as ra-
cial/ethnic minority models.27 These innovative, sex-positive
social marketing campaigns should be adopted by health de-
partments in other jurisdictions. In addition, the State of Cali-
fornia now requires information about PrEP to be delivered
with HIV post-test counseling through the recently passed
AB 2640.28
In addition to these efforts underway, high school sexual
education curricula should consider including PrEP as an
HIV prevention option as many already do with condoms.
Although conversations on LGBT health issues are not
often included in such curricula,29 PrEP can be discussed
as an option that is available for everyone regardless of
gender or sexual orientation. Individual-level education
may confer the additional benefit of reducing social stigma
and fear of side effects that may be associated with PrEP
and result in greater willingness to try one or more formu-
lations of PrEP as they become available. These multilevel
efforts can provide more widespread understanding of
PrEP and allow more individuals to decide whether PrEP
is right for them.
Approximately 10% (n = 15) of individuals who had a
high-risk score according to the CDC PrEP screener stated
that they were unwilling to try either injectable or on-
demand PrEP. While this group is small, it is important
to understand why these individuals are not amenable to
any form of PrEP since these high-risk individuals could
benefit the most from PrEP use. By understanding the fac-
tors that drive individuals from PrEP contemplation to
PrEParation along the motivational PrEP cascade, we can
more fully ensure that at-risk individuals are educated
about all HIV prevention strategies.8
Limitations
This study has important limitations as well as notable
strengths. First, the survey was asked among a convenience
sample of YMSM living in California who were recruited
through geosocial networking apps. Therefore, it may not
be generalizable to older MSM, younger MSM who do
not use geosocial networking apps in California, and/or
YMSM outside of California. Second, due to the small sam-
ple size of the subset analyzed, we may not have been able
to detect associations in multivariable models due to power
issues (i.e., Type II errors). Third, intentions to use PrEP
may not reflect actual usage trends. In a study comparing
willingness and intentions to use PrEP, Rendina et al.
found that 43% of respondents were unwilling, 41% were
willing but not intending, and 16% were willing and intend-
ing to take PrEP.30 These differences highlight the need to
further incorporate intentions into future surveys of poten-
tial PrEP users. Fourth, these proportions must be inter-
preted cautiously as recent data indicate that injectable
PrEP needs to be administered at 2-month intervals as op-
posed to the quarterly timeframe asked about in the present
and previous studies.16,17 Greater frequency of injectable
PrEP formulations may lower acceptability of this formula-
tion for certain groups. Furthermore, the acceptability of
on-demand PrEP was ascertained by asking the following
question, ‘‘Would you be more likely to take PrEP if you
only had to take the pill when you had sex instead of
every day? (Assuming that both are equally effective)?’’
On-demand PrEP requires taking two doses of FTC/TDF
between 2 and 24 hours before sexual activity and then sub-
sequently taking one dose each at 24 and 48 hours after the
initial two doses,18 and the way the question was asked
does not account for this nuance, which may bias estimates.
Fifth, our survey did not ask about reasons for not wanting
to initiate PrEP, but this information is key for future inter-
ventions that aim to increase uptake among the most at-risk
populations. Sixth, the willingness to use daily oral PrEP
question was asked on a 6-item scale, whereas the willing-
ness to use either on-demand or injectable PrEP was asked
as binary yes/no questions; this different methodology pre-
vented a more nuanced analysis of individuals who may
have been more ambivalent about these alternative forms
of PrEP. Lastly, attitudes about both once-daily oral
PrEP and alternative forms of PrEP have likely evolved
since these data were collected.
Numerous education campaigns at both the state and local
levels have led to greater uptake of PrEP. However, data
from the current study are informative given that injectable
PrEP is still undergoing clinical trials, and the findings can
be used to tailor further education efforts. Study strengths in-
clude recruitment of participants through MSM-specific
online outlets, and the possibility for reduced social desir-
ability bias due to online assessment (compared with face-
to-face assessment).
Conclusion
PrEP will only be as successful as the rate of uptake by
populations who are the most at risk for HIV infection. A
perceived inability to adhere to a daily medication may be
a significant reason for unwillingness to try daily oral
PrEP, but the reasons for rejection of either injectable or
on-demand PrEP are still unclear. It is quite possible that
as more scientific evidence supporting these alternative dos-
ing schedules becomes available, willingness to try on-
demand and injectable PrEP may increase. Future studies
should focus on the small subset of individuals who are at
risk for HIV, but who are unwilling to try any form of
PrEP. Understanding their perceptions about PrEP and per-
ceived barriers to uptake will allow HIV prevention efforts
to maximize the utility of PrEP against HIV.
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